FDA-cleared profile

AIR Recon DL

GE Medical Systems,LLC (GE Healthcare) · MRI · FDA-cleared (510(k))

AIR Recon DL is optional integrated GE MRI reconstruction that removes noise and ringing from supported 1.5T, 3T, and 7T acquisitions across all ages and anatomies.

Clinical role
Integrated MR image reconstruction that reduces noise or artifacts before routine professional interpretation.
Images and patients
MRI · Multi-region
Key limitation
The proposed AIR Recon DL is intended for use on GE Healthcare 1.5T, 3.0T, and 7.0T MR systems and has been modified to be compatible with PROPELLER and selected 3D Cartesian acquisitions.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyMRI · Multi-region
  • Workflow roleIntegrated MR image reconstruction that reduces noise or artifacts before routine professional interpretation.
  • Required inputAcquired raw data from GE Healthcare 1.5T, 3.0T, and 7.0T MR systems with PROPELLER and selected 3D Cartesian acquisitions.
  • Output and human actionAIR Recon DL images.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AIR Recon DL is optional integrated GE MRI reconstruction that removes noise and ringing from supported 1.5T, 3T, and 7T acquisitions across all ages and anatomies.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Integrated MR image reconstruction that reduces noise or artifacts before routine professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Acquired raw data from GE Healthcare 1.5T, 3.0T, and 7.0T MR systems with PROPELLER and selected 3D Cartesian acquisitions.
  • Exact FDA submission
  • Checked 2026-09-19

The packet identifies the compatible MR systems, PROPELLER and selected 3D Cartesian acquisitions, and comparison images reconstructed from the same acquired raw data; it does not state the dossier's coil and input-quality wording.

Output and clinician action
AIR Recon DL images.
  • Exact FDA submission
  • Checked 2026-09-19

The packet refers to AIR Recon DL images and does not state archival output.

Care setting
Hospital and outpatient MRI departments using compatible GE MRI systems.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
The proposed AIR Recon DL is intended for use on GE Healthcare 1.5T, 3.0T, and 7.0T MR systems and has been modified to be compatible with PROPELLER and selected 3D Cartesian acquisitions.
  • Exact FDA submission
  • Checked 2026-09-19

This is the packet's system and acquisition-scope boundary; coil, acceleration, input-quality, and physician-review requirements are not stated.

Evidence summary
K213717 reports phantom testing and a clinical reader study of 133 cases representing 129 patients from 10 sites, including 51 cases at 1.5T and 82 at 3T.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K213717 reports phantom testing and a clinical reader study of 133 cases representing 129 patients from 10 sites, including 51 cases at 1.5T and 82 at 3T.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Clinical reader-study cases

133 cases

  • EndpointAIR Recon DL image-quality evaluation
  • PopulationAIR Recon DL
  • Tested versionAIR Recon DL release cleared in K213717

Patient records

129 patients

  • EndpointClinical reader-study population
  • PopulationAIR Recon DL
  • Tested versionAIR Recon DL release cleared in K213717

K213717 FDA performance package for AIR Recon DL

  • DesignManufacturer phantom testing and multicenter clinical reader study
  • Population133 MRI cases across 1.5T and 3T systems, multiple anatomies, and supported sequences
  • Scopeexact submission
  • Tested versionAIR Recon DL release cleared in K213717
  • Samplen=133
  • Sites10
  • IndependenceSponsor or vendor study

K213717

Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K213717 by exact submission identifier. This does not exclude product-family or later safety information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Acquired raw data from GE Healthcare 1.5T, 3.0T, and 7.0T MR systems with PROPELLER and selected 3D Cartesian acquisitions.

    Scope: Exact FDA submission. The packet identifies the compatible MR systems, PROPELLER and selected 3D Cartesian acquisitions, and comparison images reconstructed from the same acquired raw data; it does not state the dossier's coil and input-quality wording.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K213717: AIR Recon DL

  2. Routing

    Source context, not route validation: Integrated scanner reconstruction followed by normal DICOM export; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K213717: AIR Recon DL · GE HealthCare AIR Recon DL

  3. AI processing

    Source context, not route validation: Licensed software integrated into supported GE MRI scanner configurations.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K213717: AIR Recon DL · GE HealthCare AIR Recon DL

  4. Returned objects

    Source context, not route validation: AIR Recon DL images.

    Scope: Exact FDA submission. The packet refers to AIR Recon DL images and does not state archival output.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K213717: AIR Recon DL

  5. Viewer/worklist/report

    Unresolved route: AIR Recon DL images.

    Scope: Exact FDA submission. The packet refers to AIR Recon DL images and does not state archival output.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K213717: AIR Recon DL

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Licensed software integrated into supported GE MRI scanner configurations.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Integrated scanner reconstruction followed by normal DICOM export; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.
  • Exact FDA submission
  • Checked 2026-09-03
Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only qualified mri technologists and interpreting physicians. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Performance depends on supported scanner, field strength, coil, sequence, anatomy, acceleration, and input quality; reconstructed images remain subject to physician review.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K213717 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Integrated scanner reconstruction followed by normal DICOM export; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Performance depends on supported scanner, field strength, coil, sequence, anatomy, acceleration, and input quality; reconstructed images remain subject to physician review.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Performance depends on supported scanner, field strength, coil, sequence, anatomy, acceleration, and input quality; reconstructed images remain subject to physician review.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K213717
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-06-08
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Documented product family

Related FDA records

These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.

AIR Recon DL

Open the documented family

A partial mapping of two reviewed FDA submissions. Evidence, compatible inputs, licensing and availability remain specific to each record.

The K252379 summary explicitly describes a modification of AIR Recon DL K213717. The phase-correction enhancement needs an additional software option key. Scanner-system records are not included.

Mapped FDA decisions, earliest first

Latest mapped does not mean latest sold or installed. Choose an exact FDA record before comparing.

  1. This FDA recordAIR Recon DL (K213717)

    AIR Recon DL in K213717

    FDA decision: 2022-06-08 · record reviewed 2026-11-09
  2. Related FDA recordAIR Recon DL (K252379)

    AIR Recon DL with Phase Correction in K252379

    Latest mapped FDA decisionFDA decision: 2025-12-23 · record reviewed 2026-11-09

Documented names and scope

  • AIR Recon DL · K213717. Name for this exact FDA record, not an alias for every commercial configuration. Name source
  • AIR Recon DL with Phase Correction · K252379. Name for this exact FDA record, not an alias for every commercial configuration. Name source

AIR Recon DL

MR reconstruction to reduce noise and ringing artifacts. Applies to K213717, K252379. This describes the mapped function only; feature parity and a shared license are not established.

Availability evidence, separate from FDA decisions

  • not established

    Current availability of an exact FDA-submission configuration is not established. Ask the supplier for the offered release and licensed modules.

Latest FDA decision among these records
K252379 · 2025-12-23. Latest mapped decision only. Not automatically the latest sold or installed version, and not a supersession claim.
Latest documented release
Current commercial release or exact offered configuration is not established by this partial mapping.
Current commercial availability
Current commercial release or exact offered configuration is not established by this partial mapping.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
10Source classes checked
12Awaiting review PubMed leads
1Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 12 PubMed and 1 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 2 history items

Source ledger

  1. FDA K213717: AIR Recon DL

    U.S. Food and Drug Administration - Published 2022-06-08 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, evidenceSummary, input, output, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. GE HealthCare AIR Recon DL

    GE HealthCare - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  8. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

  9. FDA K213717: AIR Recon DL

    U.S. Food and Drug Administration - Published 2022-06-08 - Accessed 2026-11-09

    Scope: purpose, modality, anatomy, evidenceSummary, input, output, limitations, clinicalUse, product_family

  10. FDA 510(k) decision material K252379: AIR Recon DL

    U.S. Food and Drug Administration - Published 2025-12-23 - Accessed 2026-11-09

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary, product_family

Research history

  1. K213717 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K252838

MAGNETOM Sola; MAGNETOM Altea; MAGNETOM Sola Fit; MAGNETOM Viato.Mobile; MAGNETOM Vida; MAGNETOM Lumina; MAGNETOM Vida Fit; MAGNETOM Flow.Elite; MAGNETOM Flow.Neo; MAGNETOM Flow.Rise

Siemens Healthcare GmbH

Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history